Branhamella catarrhalis respiratory infections in The Netherlands.
In the southern Netherlands, Branhamella catarrhalis can be cultured from sputum in more than 20% of patients with purulent lower respiratory tract infections and approximately 40% of strains produce beta-lactamase. With increasing resistance to co-trimoxazole (10%) and erythromycin (6%) this produces many treatment problems, particularly in general practice. Recent results in the treatment of B. catarrhalis respiratory infections with newer antimicrobial agents and new combinations of beta-lactamase inhibitors are presented. Cefotaxime and ceftazidime are predictably effective but, considering their cost and the fact that they require parenteral administration, they need to be reserved for strict indications.
D002511:Cephalosporins / Q000494:pharmacology; D004318:Doxycycline / Q000494:pharmacology; D006801:Humans; D008826:Microbial Sensitivity Tests; D009346:Neisseriaceae / Q000187:drug effects; D009426:Netherlands; D011804:Quinolines / Q000494:pharmacology; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*
D002511:Cephalosporins; D011804:Quinolines; D004318:Doxycycline